A nine-month, open-label randomized, active controlled phase III study of ALN-AT3 in subjects with severe haemophilia A or B with inhibitors.

Trial Profile

A nine-month, open-label randomized, active controlled phase III study of ALN-AT3 in subjects with severe haemophilia A or B with inhibitors.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Fitusiran (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS-INH
  • Most Recent Events

    • 10 Jul 2017 According to a Sanofi Genzyme media release, if positive data will support global regulatory filings for fitusiran.
    • 07 Jul 2017 According to an Alnylam Pharmaceuticals media release, top-line data from the ATLAS trials expected in mid-to-late 2019
    • 07 Jul 2017 Status changed from planning to recruiting, according to a Sanofi Genzyme media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top